Comparison of Efficacy and Safety of High-Dose Isotretinoin versus Low-Dose Isotretinoin with Pulsed Oral Azithromycin in Moderate to Severe Acne Vulgaris
Abstract
To evaluate and compare the efficacy and safety of high-dose isotretinoin with low-dose isotretinoin combined with pulsed oral azithromycin in patients with moderate to severe acne vulgaris.
This comparative clinical study included patients diagnosed with moderate to severe acne based on the Global Acne Grading Score (GAGS). Participants were divided into two treatment groups: Group A (31 patients) received high-dose isotretinoin, while Group B (31 patients) received low-dose isotretinoin with pulsed oral azithromycin. Patients were followed monthly, and outcomes were assessed in terms of reduction in GAGS and incidence of adverse effects.
Both treatment regimens resulted in significant clinical improvement. High-dose isotretinoin demonstrated a faster and more pronounced reduction in acne severity. However, the combination regimen achieved comparable overall improvement with a lower frequency of adverse effects.
Low-dose isotretinoin combined with pulsed azithromycin provides an effective and better-tolerated alternative without significant side effects and being cost-effective, whereas high-dose isotretinoin remains superior for rapid clinical clearance.
How to Cite This Article
Saif S, Ghias A, Nusrat W, Sinai M, Alam FN. Comparison of Efficacy and Safety of High-Dose Isotretinoin versus Low-Dose Isotretinoin with Pulsed Oral Azithromycin in Moderate to Severe Acne Vulgaris. J Pak Soc Intern Med. 2026;7(4):349–351. doi:10.70302/jpsim.v7i4.2669
Conflict of Interest
The authors declare no conflict of interest.
Funding
This research received no specific grant from any funding agency.
Funder information follows the Crossref Funder Registry standard.
Author Contributions
SS: Conception.
AG: Design of the work.
WN, MS, FNA: Data acquisition, analysis, or interpretation.
AG,WN, MS, FNA: Draft the work.
SS: Review critically for important intellectual content.
All authors approve the version to be published.
All authors agree to be accountable for all aspects of the work.
Contributions are recorded against the ICMJE criteria for authorship.
Data Availability
Data are available from the corresponding author on reasonable request.
Ethics Statement
This study was approved by Institutional Review Board, King Edward Meidcal University, Lahore. Approval number: 11093/RG/KEMU/2016, dated November 28, 2016.
Conducted in accordance with the Declaration of Helsinki.
References
- Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54(4):644-6.
- Hermes B, Praetel C, Henz BM. Low-dose isotretinoin therapy. J Dtsch Dermatol Ges. 2005;3:449-53.
- Mandekou-Lefaki I, Delli F, Teknetzis A, Euthimiadou R, Karakatsanis G. Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharmacol Res. 2003;23(2-3):41-6.
- Goulden V, Clark SM, McGeown C, Cunliffe WJ. Treatment of acne with intermittent isotretinoin. Br J Dermatol. 1997;137(1):106-8.
- Batool A, Abbas MS, Ali Akbar M, Murtaza M, Mahin FE, Ali U, et al. Comparative efficacy and safety of oral azithromycin versus doxycycline in moderate-to-severe Acne vulgaris: a systematic review and meta-analysis. J Dermatol Treat. 2026;37(1):2648406.
- Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. Pediatrics. 2006;118(3):1188-99.
- Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, Chen W, Nagy I, Picardo M, Suh DH, Ganceviciene R. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009;18(10):821-32.
- Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361-72.
- Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris—10 years later; a safe and successful treatment. Br J Dermatol. 1993;129(3):292-6.
- Thiboutot D, Layton AM, Traore I, Gontijo G, Troielli P, Ju Q, et al. International expert consensus recommendations for the use of dermocosmetics in acne. J Eur Acad Dermatol Venereol. 2025;39(5):952-66.
Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.